• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Endocrinology and Metabolism >Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
【24h】

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience

机译：斋月中的胰岛素degludec和胰岛素degludec /门冬胰岛素：单中心体验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study aimed to document the utility and safety of insulin degludec (IDeg) and insulin degludec aspart (IDegAsp) in persons with type 2 diabetes, observing the Ramadan fast. An observational study was conducted at a single center, in the real world setting, on six persons who either switched to IDeg or IDegAsp a month before Ramadan or changed time of administration of IDegAsp at the onset of Ramadan, to keep the fast in a safe manner. Subjects were kept under regular monitoring and surveillance before, during, and after Ramadan, and counseled in an opposite manner. Four persons, who shifted from premixed insulin to IDegAsp, experienced a 12–18% dose reduction after 14 days. At the onset of Ramadan, the Suhur dose was reduced by 30%, and this remained unchanged during the fasting month. The Iftar dose had to be increased by 4 units. One person who shifted from neutral protamine hagedorn to IDeg demonstrated a 25% dose reduction at 20 days, without any further change in insulin requirement during Ramadan. One person who changed time of injection of IDegAsp from morning to night reported no change in dosage. No episode of major hypoglycemia was reported. IDeg and IDegAsp are effective, safe, and well-tolerated means of achieving glycemic control in persons with type 2 diabetes who wish to fast.
机译：这项研究的目的是记录斋戒月的斋戒月期间，胰岛素德格列酮（IDeg）和门冬胰岛素德格列茨门冬氨酸（IDegAsp）的实用性和安全性。在真实世界中的一个中心进行了一项观察性研究，研究对象是六个人，他们在斋月前一个月改用IDeg或IDegAsp，或者在斋月开始时改变IDegAsp的给药时间，以确保斋戒处于安全状态方式。在斋月之前，期间和之后，对受试者进行定期监测和监视，并以相反的方式进行咨询。从预混胰岛素转变为IDegAsp的四个人在14天后剂量减少了12-18％。在斋月开始时，Suhur剂量减少了30％，在斋戒月期间保持不变。开胎剂量必须增加4个单位。一个人从中性鱼精蛋白哈丁顿转变为IDeg，在斋月期间20天剂量降低了25％，胰岛素需求没有任何进一步变化。一名从早到晚更改IDegAsp注射时间的人报告剂量没有变化。没有报道严重低血糖发作。 IDeg和IDegAsp是希望禁食的2型糖尿病患者实现血糖控制的有效，安全且耐受良好的手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号